Global & USA Cancer Immunotherapy Market Analysis to 2020

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 10, 2015 at 6:30 AM

Dublin, April 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/cv...al_and_usa ) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" report to their offering.

Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone

This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures over 256 pages.

Scope

- An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies.
- Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
- Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
- Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market).
- Insight into the various immunotherapeutics available for specific cancer types.
- Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
- Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
- Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
- Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe.
- Summary table to identify the category of immunotherapy drug offered by the 76 companies.

The global market for cancer immunotherapy by the following sub-categories are presented:

- By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
- By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors
- By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)

Key Questions Answered in this Report

- What are the three types of cancer immunotherapies?
- What are the immunotherapies approved between 1986 and 2014?
- What are the monoclonal antibodies (MAbs) approved by FDA to treat different types of cancers?
- What are naked MAbs and how many of them have been approved by FDA?
- What are antibody-drug conjugates (ADCs) and how many of them are available in the market?
- What are the common cytotoxic warheads used in ADCs?
- What are the important clinical assets in ADCs?
- How many bispecific MAbs are in late-stage development?
- What are the common side effects of MAbs in cancer immunotherapy?
- What are cancer vaccines and how many of them have been licensed to be marketed?
- How many cytokines have been approved for being used in cancer immunotherapy?
- What are the major checkpoint inhibitors in clinical development?
- What is the current status of anti-PD-1 drugs, dendritic cell therapies, T-cell therapies and cancer vaccines?
- What are the most valuable R&D projects in cancer immunotherapy and what would be their approximate sales revenues in 2020?
- Number of melanoma drugs approved between 1998 and 2014?
- Number of lung cancer drugs approved between 1998 and 2014?
- Number of brain cancer drugs approved between 1998 and 2014?
- What is the global market for cancer immunotherapeutics by geography, through 2020?
- What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2020?
- What is the global market for cancer immunotherapeutics by indication, through 2020?
- What is the global market for MAbs by type such as naked MAbs and ADCs, through 2020?
- What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda?
- What is the global market for cancer vaccines?
- What is the global market for cytokines in cancer immunotherapy?
- The projected market values for Nivolumab, RG7446, DCVax-L, MEDI4736 etc.?

Companies Mentioned

- Ablynx NV
- Activartis Biotech GmbH
- Advaxis Inc.
- Aduro BioTech Inc.
- Agenus Inc.
- AlphaVax Inc.
- A. Menarini
- Amgen Inc.
- Antigen Express Inc.
- Argos Therapeutics Inc.
- Bavarian Nordic A/S
- Bellicum Pharmaceuticals Inc.
- Biogen Idec Inc.x
- Biovest International Inc.
- Bristol-Myers Squibb Co.
- Cellectis
- Cellerant Therapeutics Inc.
- Celldex Therapeutics
- CEL-SCI Corp.
- CureTech Ltd
- Delta-Vir GmbH
- Dendreon Corp.
- DenDrit Biotech USA
- DNAtrix Inc.
- Eli Lilly and Co.
- EMD Serono Inc.
- Etubics Corp.
- Galena Biopharma Inc.
- Genentech Inc.
- Genmab AS
- GlaxoSmithKline
- Gliknik Inc.
- GlobeImmune Inc.
- Heat Biologics Inc.
- Immatics Biotechnologies GmbH
- ImmunoCellular Therapeutics Ltd.
- Immunocore Ltd
- ImmunoFrontier Inc.
- ImmunoGen Inc.
- Immunomedics Inc.
- Immunotope Inc.
- Immunovaccine Inc.
- Inovio Pharmaceuticals Inc.
- Janssen Biotech Inc.
- Juno Therapeutics Inc.
- Kite Pharma Inc.
- MabVax Therapeutics Holdings Inc.
- MedImmune LLC
- Merck & Co., Inc.
- Merrimack Pharmaceuticals Inc.
- Morphotek Inc.
- NewLink Genetics Corp.
- Northwest Biotherapeutics Inc.
- NovaRx Corp.
- OncoPep Inc.
- Oncothyreon Inc.
- OSE Pharma SA
- Oxford BioTherapeutics Ltd.
- Pique Therapeutics
- Polynoma LLC
- Prima BioMed Ltd.
- Progenics Pharmaceuticals Inc.
- Regen Biopharma Inc.
- Roche Holdings Inc.
- Seattle Genetics Inc.
- Sorrento Therapeutics Inc.
- Spectrum Pharmaceuticals Inc.
- Synthon Pharmaceuticals Inc.
- TapImmune Inc.
- ThioLogics Ltd.
- Transgene SA
- TVAX Biomedical Inc.
- Vaccinogen Inc.
- Viventia Biotechnologies Inc.
- Wilex AG

For more information visit http://www.researchandmarkets.com/research/cv...al_and_usa

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aflac's $200M Milestone in Cancer Charity Support

Pioneering Efforts Across Decades Here’s an effort that bucks the usual corporate talk. Aflac, the supplemental insurance giant, isn’t just mumbling about its mission; it's doing the heavy lifting in the fight against childhood cancer and blood disorders. With over $200 million in contributions poured into the cause over more than 30 years, they're putting the capital...

IDX Expands, Enhances Team Amid 56% H1 Growth

IDX's Aggressive Global Expansion Here's a tip from a trader who’s seen cycles rise and fall: watch the movers who're playing the long game, putting down roots worldwide while making headway in the data game. IDX has clearly mapped out this trajectory as evidenced by its recent grab in the global strategic communications ring. IDX's bustling around like a squirrel...

From Kitchen Experiment to U.S. Debut Here's a story that barely fits the tight mold of your typical business textbook. Hair Syrup, born from the brain of a university student tinkering at her kitchen table, is about to make waves across the pond. Lucie Macleod did what many dream of—she took a DIY hair oil project and spun it into a multimillion-dollar brand, now set...

Agroz's Big Leap: New Supply Deal in Malaysia

Agroz Inc. Executes a Game-Changing Deal If anyone thought the ag tech players were sitting idle, think again. Agroz Inc., noted for their innovative controlled-environment agriculture, just inked a pivotal deal with Harvest Hive in Malaysia. It's not just a nod to expansion—it's a strategic leap into the big leagues. Picture this: Harvest Hive's sprawling 500-acre farm...

RevSystems Joins Elite OpenAI Partner Network

RevSystems Inks Deal with OpenAI Partner Network In the latest shuffle of the AI advisory deck, RevSystems just found itself elbowing into the exclusive OpenAI Partner Network. Based out of New York, RevSystems has carved a niche by spinning tech wizardry into tangible business results. Their new status as an OpenAI Select Partner puts them on a playing field where AI...

MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

Alif Semiconductor Unveils StartKit for Edge AI MCU Fam

Here's some clarity amidst the storm of buzzwords: Alif Semiconductor has rolled out something the market's been howling for—Edge AI that doesn't break the bank. It's less about slick press releases and more about real-world implications. We're talking accessibility with their dirt-cheap, small-form-factor StartKit platform for Ensemble and Balletto microcontrollers....

ZEEKR's Shooting Brakes Dominate: Over 400K Sold

ZEEKR's Stellar Performance in a Crowded Market Another month, another bumper crop for ZEEKR's shooting brakes. These beauties aren't just hanging in there; they're leading the pack. In August alone, global deliveries marched past the 10,000 mark for the third month running—a feat not easily achieved in today's saturated automotive landscape. It's no wonder the...

Strategic Hire: Whisenhunt Joins FlexScreen & RiteScreen

Shaking Up the Window Screens Biz If you've been grinding in the window and door game, you know it's not an industry with a lot of buzz, but here comes a shot of caffeine. FlexScreen and RiteScreen just snagged David Whisenhunt to rev up their sales machine. Who's David Whisenhunt? Well, he's no rookie. With over two decades deep in the fenestration field, Whisenhunt...

The Austin Company to Showcase at ISPE Annual Event

Setting the Stage at ISPE Expo When you think of pharmaceuticals and the bustle behind closed doors, it's with companies like The Austin Company leading the charge. This October, they're strutting their stuff at the ISPE Annual Meeting and Expo. No small potatoes here—it's at the Gaylord National in Maryland. Mark those dates: October 18-21, 2026. It's a circus of...